Hydroxychloroquine dose based upon weight and renal function

Discussion in 'Chloroquine Without A Doctors Prescription' started by drJob, 06-Mar-2020.

  1. Volchock Moderator

    Hydroxychloroquine dose based upon weight and renal function


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Hydroxychloroquine sarcoidosis hypercalcemia Plaquenil drug class Plaquenil and flagyl together

    Annual screening may be commenced before 5 years of treatment if additional risk factors for retinal toxicity exist, such as concomitant tamoxifen therapy, impaired renal function eGFR less than 60 mL/minute/1.73 m 2 or high-dose therapy greater than 5 mg/kg/day of hydroxychloroquine sulfate. The usual dose is 200 – 400mg daily. Dose should not exceed 5mg/kg actual body weight and should be adjusted according to renal function. See table 4 in the BSR monitoring guideline for recommended dosing in CKD. Doses should be taken with a meal or a glass of milk. Available Preparations Hydroxychloroquine is available as 200mg film coated. Mar 14, 2016 Regarding the dosing of hydroxychloroquine, we advocate the use of a weight based dosing regimen with a cap at 400 mg per day, except in the case of renal insufficiency, when the dose should be reduced to 200 mg per day and for those on dialysis, who should take their hydroxychloroquine, 200 mg three times per week.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Hydroxychloroquine dose based upon weight and renal function

    Drug Dosing Adjustments in Patients with Chronic Kidney., HYDROXYCHLOROQUINE

  2. Plaquenil bradycardia
  3. Compound chloroquine section top
  4. Dosages of drugs cleared renally are based on renal function calculated as GFR or creati-nine clearance; Table 3. These calculations are valid only when renal function is stable

    • Drug Dosing Adjustments in Patients with Chronic Kidney Disease.
    • The Role of Hydroxychloroquine Blood Levels in SLE RheumNow..
    • Hydroxychloroquine Dosage Guide with Precautions -.

    Apr 03, 2016 Regarding the dosing of hydroxychloroquine, we advocate the use of a weight-based dosing regimen with a cap at 400 mg per day, except in the case of renal insufficiency, when the dose should be reduced to 200 mg per day and for those on dialysis, who should take their hydroxychloroquine at 200 mg three times per week. All patients in the cohort were prescribed hydroxychloroquine not to exceed a dose of 6.5 mg per kilogram. The maximum daily dose prescribed is 400 mg. In those who are on hemodialysis 200 mg was prescribed after each dialysis session. In those with renal insufficiency, the dose was 200mg daily. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function. Weight-based dosing in adults and pediatric patients 6.5 mg/kg 5 mg/kg base. PLAQUENIL- hydroxychloroquine sulfate tablet

     
  5. Attache Well-Known Member

    Hydroxychloroquine is a quinoline medicine used to treat or prevent malaria, a disease caused by parasites that enter the body through the bite of a mosquito. Drugs That Can Interfere With Plaquenil Hydroxychloroquine Side Effects, Dosage, Uses, and More Drug Interactions With Allopurinol
     
  6. nickon Guest

    Elevated liver enzymes often indicate inflammation or damage to cells in the liver. Rheumatoid Arthritis & Elevated Liver Enzymes Healthfully What Causes Slightly Elevated Liver Enzymes? ALT Alanine Aminotransferase Test Purpose, Procedure, and.
     
  7. g0rn User

    PLAQUENIL Prescription Price Comparison Compare Drug Prices. Use our prescription price comparison tool to find the best prescription drug price for PLAQUENIL in your area. Manufacturer Coupons and Offers Available. offer.

    PLAQUENIL Patient Assistance Program